Combination therapy strengthens T cells in melanoma pre-clinical study

April 17, 2018, University of Texas M. D. Anderson Cancer Center

A pre-clinical study of two drugs designed to boost T cell performance, has revealed the agents, when give in combination, may enhance the immune system's ability to kill melanoma tumors deficient in the tumor suppressor gene PTEN. The study was led by investigators at The University of Texas MD Anderson Cancer Center.

The study combined OX40 agonist antibody and GSK2366771. OX40 is a protein critical to cell signaling required for T to fully function; while OX40 agonist antibodies are drugs that make the process more efficient. GSK236671 is an investigational drug that inhibits a pathway often linked to called PI3K. Together, the agents appear to be the cellular equivalent of stepping on the gas, revving up T cells and providing the extra power they need to more efficiently kill cancer cells.

Study findings were presented today at the American Association for Cancer Research Annual Meeting 2018 in Chicago. The study results builds on prior investigations by the research team which demonstrated that activation of the PI3K pathway by PTEN loss created a "microenvironment" allowing tumors to evade immune suppression.

"In our latest study, results suggest that the combination of an OX40 agonist antibody and GSK2636771 may induce robust and durable antitumor T-cell immunity," said Weiyi Peng, M.D., Ph.D., assistant professor of Melanoma Medical Oncology, and co-lead of the study. "These results also provide a rationale to explore the clinical activity of an OX40 agonist antibody in combination with GSK2636771 in cancer patients with PTEN loss tumors."

PTEN loss occurs in many cancers including breast, colorectal, prostate and others. By using a model of melanoma, the team was able to spontaneously develop tumors with PTEN loss, and observe the .

"We saw significantly delayed tumor growth and improved survival time of mice bearing PTEN loss tumors," said Patrick Hwu, M.D., division head of Cancer Medicine and principal investigator of the study. "This combinational treatment also was well tolerated and enhanced the number of CD8 T cells at the tumor site. These results suggest GSK2636771 treatment can 'synergize' with OX40 agonist antibodies to augment effector functions of tumor-reactive T cells."

To confirm this synergistic effect, the team measured of signaling proteins in tumor-bearing mice receiving OX40 agonist antibodies alone or in combination with GSK2636771. Serum levels of proteins secreted by powerful memory or effector T cells, which are longer lasting and more capable of "remembering" , were significantly increased in the combination therapy versus OX40 agonist antibody alone.

Explore further: Concurrent treatment with OX40- and PD1-targeted cancer immunotherapies may be detrimental

Related Stories

Concurrent treatment with OX40- and PD1-targeted cancer immunotherapies may be detrimental

August 28, 2017
Concurrent administration of the T-cell stimulating anti-OX40 antibody and the immune checkpoint inhibitor anti-PD1 antibody attenuated the effect of anti-OX40 and resulted in poor treatment outcomes in mice.

Study finds relationship between PTEN loss, potential for immune response in BRCA 1/2-deficient ovarian cancer

April 16, 2018
The protein known as phosphatase and tensin homolog (PTEN) is frequently mutated or affected by cancer as tumors develop. Now a new study from the Basser Center for BRCA at the Abramson Cancer Center of the University of ...

Mouse model exposes a new type of T cell to target melanoma

October 24, 2012
Cancers arise in the body all the time. Most are nipped in the bud by the immune response, not least by its T cells, which detect telltale molecular markers—or antigens—on cancer cells and destroy them before they grow ...

Combination immunotherapy targets cancer resistance

November 22, 2017
Cancer immunotherapy drugs have had notable but limited success because in many cases, tumors develop resistance to treatment. But researchers at Yale and Stanford have identified an experimental antibody that overcomes this ...

Cancer 'vaccine' eliminates tumors in mice, researchers find

January 31, 2018
Injecting minute amounts of two immune-stimulating agents directly into solid tumors in mice can eliminate all traces of cancer in the animals, including distant, untreated metastases, according to a study by researchers ...

Gene variant may provide novel therapy for several cancer types

June 7, 2013
(Medical Xpress)—A novel gene variant found in human and animal tissue may be a promising treatment for cancer, including breast and brain cancer, according to scientists from the Icahn School of Medicine at Mount Sinai. ...

Recommended for you

Fusion hybrids: A newly discovered population of tumor cells

September 24, 2018
In a recent study published in Science Advances, Charles E. Gast and co-workers detail the spontaneous process of cancer cell fusion with white blood cells to produce heterogenous hybrid clones in multiple biological systems, ...

Cancer cells evade immunotherapy by hiding telltale marker, suggesting how to stop relapse

September 24, 2018
Harnessing the immune system to treat cancer shows great promise in some patients, but for many, the response does not last long-term. In an effort to find out why, Fred Hutchinson Cancer Research Center scientists are using ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.